Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cemiplimab by Regeneron Pharmaceuticals for Angiosarcoma: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...
Cemiplimab by Regeneron Pharmaceuticals for Acral Lentiginous Melanoma: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Acral Lentiginous Melanoma. According to GlobalData,...
Alirocumab by Regeneron Pharmaceuticals for Sepsis: Likelihood of Approval
Alirocumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Sepsis. According to GlobalData, Phase I...
Cemiplimab by Regeneron Pharmaceuticals for Metastatic Pancreatic Cancer: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Cemiplimab by Regeneron Pharmaceuticals for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Hormone-Sensitive Prostate Cancer. According to GlobalData,...
Cemiplimab by Regeneron Pharmaceuticals for Oropharyngeal Cancer: Likelihood of Approval
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
Odronextamab by Regeneron Pharmaceuticals for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma. According to...
Odronextamab by Regeneron Pharmaceuticals for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
Dupilumab by Regeneron Pharmaceuticals for Gastritis: Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Gastritis. According to GlobalData, Phase III...
Dupilumab by Regeneron Pharmaceuticals for Gastroenteritis: Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Gastroenteritis. According to GlobalData, Phase III...
Dupilumab by Regeneron Pharmaceuticals for Bullous Pemphigoid: Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase...
Dupilumab by Regeneron Pharmaceuticals for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData,...
Linvoseltamab by Regeneron Pharmaceuticals for Refractory Multiple Myeloma: Likelihood of Approval
Linvoseltamab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Refractory Multiple Myeloma. According to GlobalData, Pre-Registration...
Linvoseltamab by Regeneron Pharmaceuticals for Relapsed Multiple Myeloma: Likelihood of Approval
Linvoseltamab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Relapsed Multiple Myeloma. According to GlobalData, Pre-Registration...
Pozelimab by Regeneron Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval
Pozelimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase...
Odronextamab by Regeneron Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Dupilumab by Regeneron Pharmaceuticals for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Chronic Obstructive Pulmonary Disease (COPD). According to...
REGN-7999 by Regeneron Pharmaceuticals for Iron Deficiency Anemia: Likelihood of Approval
REGN-7999 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Iron Deficiency Anemia. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Regeneron Pharmaceuticals's Fianlimab?
Fianlimab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Phase III program in Squamous Non-Small Cell Lung...
Risk adjusted net present value: What is the current valuation of Regeneron Pharmaceuticals's Linvoseltamab?
Linvoseltamab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Pre-Registration program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma....